Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kenvue Inc. Common Stock (NY:KVUE)

14.24 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kenvue Inc. Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
KVUE INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Inquire About Securities Class Action Investigation – KVUE
From Rosen Law Firm
Via Business Wire
2 Incredibly Cheap Dividend Stocks to Buy Now
High-quality dividend stocks are rarely cheap. These two names are an exception. 
Via The Motley Fool
Check Out What Whales Are Doing With KVUE
 
Via Benzinga
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
Discover how these seven standout companies offer both security and growth potential in an uncertain financial landscape. 
Via InvestorPlace
Looking Into Kenvue's Recent Short Interest
 
Via Benzinga
3 High-Quality Dividend Stocks Yielding 3%-Plus to Buy for Decades of Rising Income
These companies generate durable and growing cash flows. 
Via The Motley Fool
Kenvue Unusual Options Activity For September 13
 
Via Benzinga
Better Buy: J&J vs. Kenvue
You can count on both of these companies for passive income, too. 
Via The Motley Fool
Why Jim Cramer Warns Investors To Avoid This Stock Up Over 90% This Year
On CNBC’s "Mad Money Lightning Round," Jim Cramer said UiPath Inc. (NYSE: PATH) is a "decent" stock. Cramer said the company is not making money, and he doesn’t recommend stocks that don’t make money. 
Via Benzinga
3 Great Dividend Stocks You Can Buy for Less Than $50
These steady-Eddie operators are perfect bedrock stocks for investors despite trading for less than $50. 
Via The Motley Fool
3 Blue-Chip Stocks to Watch in the ‘Green Zone’
Now may be the time to take a look at these three blue-chips, as each one is currently in the "Green Zone stocks" category. 
Via InvestorPlace
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
Analyst Ratings for Kenvue
 
Via Benzinga
Kenvue Unusual Options Activity
 
Via Benzinga
Is J&J a Buy After the Kenvue Separation?
J&J shares have been on the decline. 
Via The Motley Fool
Kenvue Unusual Options Activity For September 01
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 11, 2023
 
Via Benzinga
Bargain Hunting With $100? This New S&P 500 Dividend Stock Is a No-Brainer to Buy on the Dip
The market may be sleeping on this dividend stock, down 19% in its short history as a stand-alone business. 
Via The Motley Fool
Topics Stocks
The 7 Best Dow Stocks to Buy Now: September 2023
These are the best Dow stocks to buy because they offer long-term growth, a margin of safety and reliability in an otherwise volatile market. 
Via InvestorPlace
Topics Stocks
J&J Spinoff Kenvue is the New Dividend Aristocrat on the Block
Newly public company Kenvue, a spinoff from Johnson & Johnson, joins the ranks of dividend aristocrats, offering a 3.57% yield, and 2022 sales of $15 billion. 
Via MarketBeat
Topics ETFs
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
 
Via Benzinga
1 Brand-New Dividend Stock Income Investors Won't Want to Miss
The recently spun-off Kenvue looks to be a high-quality dividend stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
 
Via Benzinga
Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories
Benzinga Why Facebook News is Shutting Down in Europe: What It Means for Users? 
Via Benzinga
Johnson & Johnson's Growth Strategy Post Tylenol Parent Kenvue Split: Paving the Way for Medical Innovation
Johnson & Johnson (NYSE: JNJ) is gearing up to use the proceeds from the recent separation of its consumer-health segment Kenvue Inc (NYSE: KVUE) to bolster its growth in  
Via Benzinga
Is This Incredible Dividend Stock Still a Buy Following Its Recent Split?
Johnson & Johnson has completed its separation of Kenvue. 
Via The Motley Fool
Set and Forget: 3 Dividend Stocks Perfect for Your IRA
Here are three of the best dividend stocks that long-term investors looking to build out their IRAs may want to consider. 
Via InvestorPlace
Johnson & Johnson Reveals Updated 2023 Projections After Finalizing Biggest Shake Up In 135 Years
Johnson & Johnson (NYSE: JNJ) has unveiled 2023 projections, predicting double-digit profit growth after its recent spinoff of consumer hea 
Via Benzinga
1 Top Dividend Stock to Buy Hand Over Fist Right Now
Kenvue stands out as a leading dividend provider. 
Via The Motley Fool
7 Very Oversold Warren Buffett Stocks to Buy Right Now
Here are seven Warren Buffett stocks to buy in a volatile market, each one showing many of the characteristics that Buffett is so fond of. 
Via InvestorPlace
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback